Med. praxi. 2021;18(2):133-139

Drug-induced acute kidney injury

MUDr. Michal Prokeš, PharmDr. Josef Suchopár
DrugAgency, a. s., Praha

Drug-induced acute kidney injury (AKI) is a relatively common adverse event, and in some cases, drugs that have long-term nephroprotective properties may also contribute to it. This article provides basic information about the pathogenesis of AKI, the risk factors for AKI, and the symptoms of AKI, and contains a list of drugs that are associated with the development of AKI.

Keywords: acute kidney injury, triple-whammy, NSAID, RAAS inhibitors, diuretics.

Published: April 30, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. Drug-induced acute kidney injury. Med. praxi. 2021;18(2):133-139.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kolečková M, Tichý T. Polékové poškození ledvin. Klin Farmakol Farm 2018; 32: 14-19. Go to original source...
    2. Chawla LS, et al. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol 2014; 9: 448-456. Go to original source... Go to PubMed...
    3. Doporučení k vyšetřování glomerulární filtrace. Doporučení České nefrologické společnosti a České společnosti klinické biochemie ČLS JEP, 2013. Dostupné z: https://www.nefrol.cz/odbornici/doporucene-postupy-cns.
    4. Vachek J, et al. Akutní poškození ledvin. Kardiol Rev Int Med 2014; 16: 57-61.
    5. Wonnacott A, et al. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol 2014; 9: 1007-1014. Go to original source... Go to PubMed...
    6. Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf 2008; 7: 679-690. Go to original source... Go to PubMed...
    7. Pedrós C, et al. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol 2016; 72: 219-226. Go to original source... Go to PubMed...
    8. Xue JL, et al. Incidence and mortality of acute renal failure in medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17: 1135-1142. Go to original source... Go to PubMed...
    9. Prieto-García L, et al. mechanismus of triple whammy acute kidney injury. Pharmacol Ther 2016; 167: 132-145. Go to original source... Go to PubMed...
    10. Camin RM, et al. Acute kidney injury secondary to combination of renin-angiotensin systém inhibitors, diuretics and NSAIDs: "the triple whammy". Nefrologia 2015; 35: 197-206. Go to original source... Go to PubMed...
    11. Dreischulte T, et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin systém inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015; 88: 396-403. Go to original source... Go to PubMed...
    12. Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. Semin Nephrol 1997; 17: 3-14. Go to PubMed...
    13. Markowitz GS, et al. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005; 351: 31-47. Go to original source... Go to PubMed...
    14. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008; 78: 743-750. Go to PubMed...
    15. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60: 804-817. Go to original source... Go to PubMed...
    16. Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin AJ Am Soc Nephrol 2017; 12: 2046-2049. Go to original source... Go to PubMed...
    17. Douros A, et al. Drug-induced kidney injury: a large case series from the Berlin Case-Control Surveillance Study. Clin Nephrol 2018; 89: 18-26. Go to original source... Go to PubMed...
    18. Perazella MA. Pharmacology behind common drug nephrotixicities. Clin J Am Soc Nephrol 2018; 13: 1897-1908. Go to original source... Go to PubMed...
    19. Shahrbaf FG, Assadi F. Drug-induced renal disorders. J Renal Inj Prev 2015; 4: 57-60.
    20. Piereson-Marchandise M, et al. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017; 83: 1341-1349. Go to original source... Go to PubMed...
    21. Zhang X, et al. Non-steroidal anti-inflammatory drug Induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 2017; 18(1): 256. doi: 10.1186/s12882-017-0673-8 Go to original source... Go to PubMed...
    22. Gayat E, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers in post-ICU discharge outcome in patients with acute kidney injury. Intensive Care Med 2018; 44: 598-605. Go to original source... Go to PubMed...
    23. Saly DL, Perazella MA. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol 2017; 313: F951-F954. doi: 10.1152/ajprenal.00250.2017. Go to original source... Go to PubMed...
    24. FDA Adverse Event Reporting System (FAERS) Public Dashboad [cit. 2020-03-23]. Dostupné z: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.
    25. Perlman A, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report systém database. Nutr metqab Cardiovasc Dis 2017; 27: 1108-1113. Go to original source... Go to PubMed...
    26. FDA Drug Safety Communitation 6-14-2016: FDA strenghtens kidney warning for diabetes Medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XE). Dostupné z: https://www.fda.gov/media/98683/download.
    27. Perlman A, et al. Clinical spectrum and mechanism of acute kidney injury in patients with DM on SGLT-2 inhibitors. IMAJ 2018; 20: 513-515. Go to PubMed...
    28. EMA: EPAR-Product Information Invokana (kanagliflozin), Muntipharma 2020/2. Dostupné z: https://www.ema.europa.eu/en/medicines/human/EPAR/invokana#product-information-section
    29. Kubát K, et al. 23 případů metforminem indukované metabolické laktátové acidózy. Klin Biochem Metab 2017; 15: 77-85.
    30. Svoboda L. Poškození ledvin kontrastní látkou. Med. Pro Praxi 2007; 4: 410-415.
    31. SPC ČR: Siofor (metformin), Berlin-Chemie, 2020/7. Dostupné z: http://www.sukl.cz/modules/medication/search.php)

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.